Innovative Therapeutics in Oncology and Neuroscience
36
Probability of Progression-Free Survival
Bemarituzumab
BTD Granted (+ mFOLFOX) in FGFR2b≥10% Gastric Cancer by FDA and NMPA
In Patients with FGFR2b+≥10% (IHC 2+/3+ ≥10% Patients*, n=96), Bemarituzumab + mFOLFOX6
Demonstrated Even Greater Benefit in mPFS 14.1m vs 7.3m and mOS 25.4m vs 11.1m
Progression Free Survival
1.00-
0.75-
0.50-
0.25-
0.00-
BEMA
PLACEBO
Bema
n=44
Placebo
n=52
1.00
mPFS,
months
14.1
7.3
(6.8-NR) (5.4-8.2)
57.0%
(95% CI)
Hazard ratio for
Probability of
Survival
disease progression or
26.4%
death, 0.44 (95% CI,
0.25-0.77)
0.25-
Overall Survival
Late-stage
Bema
n=44
Placebo
n=52
MOS,
25.4
11.1
0.75-
170.8%
months
(13.8-NR) (8.4-13.9)
(95% CI)
48.9%
0.50-
Hazard ratio for
death, 0.41 (95% CI,
0.23-0.74)
0
T
3
Number at risk
9.
12
15
18
Months
44
35
52
36
22
23
16
21
10
7
4
10
5
1
10
Current Status
Zai Lab continues to enroll patients into global Ph3
FORTITUDE-101 and FORTITUDE-102 studies
0.00-
T
0
3
6
9
12
15 18
21 24 27
Months
Number at risk
BEMA
PLACEBO
44
40
52
33.
36 31 27
43 37 26 19
38
295
222
32
14
0
0
24 19 10
12 7
Core Opportunity
~30% (~126K annual incidence) of 1L HER2- gastric cancer
patients are FGFR2b-positive and ~18% (~76K annual
incidence) have FGFR2b expression over 10%
* Median follow-up time of 12.5 months.
Abbreviation: Immunohistochemistry (IHC).
Source: Wainberg ZA, et al. Lancet Oncol. 2022;23(11):1430-1440; Five Prime Therapeutics presentation on FIGHT trial, November 2020;
Clinical Data -
OncologyView entire presentation